News Article

Jaguar LAA has completed the acquisition of Johnson & Johnson’s Laminar program assets in a transaction that highlights a significant pivot in the cardiovascular medical technology landscape.

Announced on September 11, 2026, the deal involves the transfer of a differentiated left atrial appendage closure technology from the global healthcare giant to a newly formed, independent firm.

While the specific financial terms of this divestment remain undisclosed, Johnson and Johnson originally acquired the Laminar business in late 2023 for an upfront payment of $400m.

The Laminar program focuses on a novel catheter-based approach to addressing non valvular atrial fibrillation, a heart rhythm disorder that significantly increases the risk of stroke. Unlike established competitors such as Boston Scientific’s Watchman or Abbott’s Amulet, which use plug-based mechanisms to occlude the left atrial appendage, the Laminar technology utilizes rotational motion to eliminate the appendage entirely.

For operators and investors, the primary value proposition of this device is its ability to leave minimal metal exposure within the left atrium, potentially reducing the long term complications associated with larger implants.

This acquisition is a watershed moment in the medtech sphere as it reflects a shift in risk appetite among major strategics versus specialised investors. The move validates a broader industry trend where mature pharmaceutical and medtech firms are increasingly willing to divest promising but complex assets to specialist groups capable of focused technical iteration.